As previously reported, the Ontario Court of Appeal (ONCA) granted Sanofi and Schering leave to amend their defences to plead the Supreme Court of Canada’s decision in AstraZeneca Canada Inc. v Apotex Inc., 2017 SCC 36 (“AstraZeneca”). In the underlying action, Apotex relies on Sanofi-Aventis Canada v Apotex Inc., 2009 FC 676 (“invalidity decision”) as a central element of its novel claims under the Ontario Statute of Monopolies, U.K. Statute of Monopolies and Trade-Marks Act. The invalidity decision found certain claims of Canadian Patent No. 1,341,206 invalid on the basis of the “promise doctrine”, which was subsequently rejected as “unsound” in AstraZeneca. The ONCA concluded that depriving Sanofi and Schering of the opportunity to argue that the invalidity decision is suspect would be “fundamentally unfair”. On January 7, 2019, Apotex applied for leave to appeal to the Supreme Court of Canada (docket No. 38471).
Related Publications & Articles
-
Supreme Court of Canada dismisses Apotex’s application for leave to appeal macitentan inducing infringement decision
On June 6, 2024, the Supreme Court of Canada dismissed Apotex’s application for leave to appeal (Docket No. 41087).Read More -
Supreme Court of Canada dismisses Apotex and Pharmascience’s applications for leave to appeal paliperidone inducing infringement decisions
On June 27, 2024, the Supreme Court of Canada dismissed Apotex and Pharmascience’s applications for leave to appeal (Docket Nos. 41162 and 41164).Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More